Skip to main content
. Author manuscript; available in PMC: 2021 Apr 8.
Published in final edited form as: Circulation. 2020 May 6;141(23):1859–1869. doi: 10.1161/CIRCULATIONAHA.119.044697

Figure 2. Risk of Bias Assessment.

Figure 2.

Risk of bias is assessed for components of each study with green (+) indicating low risk, red (−) indicating high risk, and yellow (?) indicating uncertain risk. The unique design of the Zilver PTX study, with a secondary randomization to paclitaxel, increased the potential for bias with regards to the choice of analysis and the interpretation